Ze Qian1, Wendi Hu1, Zhen Lv1, Hua Liu1, Diyu Chen1, Yacong Wang2, Jian Wu3, Shusen Zheng4. 1. Division of Hepatobiliary, Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China; Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China; Collaborative innovation center for Diagnosis treatment of infectious diseases, Hangzhou, China. 2. Department of Gerontology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. 3. Division of Hepatobiliary, Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China; Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China; Collaborative innovation center for Diagnosis treatment of infectious diseases, Hangzhou, China. Electronic address: drwujian@zju.edu.cn. 4. Division of Hepatobiliary, Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China; Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China; Collaborative innovation center for Diagnosis treatment of infectious diseases, Hangzhou, China. Electronic address: shusenzheng@zju.edu.cn.
Abstract
BACKGROUND: Although pyruvate kinase M2 (PKM2) has been shown to be among the crucial enzymes that regulate aerobic glycolysis in multiple tumour cells, its role in the treatment and prognosis of intrahepatic cholangiocarcinoma (ICC) remains unclear. This study primarily aimed to determine whether the expression status of PKM2 is potentially associated with the clinical outcomes of ICC. METHODS: PKM2 expression was evaluated in ICC cell lines and tissues via real-time quantitative reverse-transcription polymerase chain reaction, immunofluorescence assays, and Western blot, and its prognostic value was determined according to its impact on the overall survival of patients. RESULTS: We found that PKM2 is highly expressed in ICC, and this was correlated with patient survival. Moreover, we found that PKM2 knockdown could considerably inhibit ICC cell proliferation, invasion, and migration in vitro. CONCLUSIONS: PKM2 was overexpressed in ICC, and it may regulate proliferation, invasion, and migration and lead to poor prognosis. Thus, PKM2 might be a potential independent prognostic factor for ICC.
BACKGROUND: Although pyruvate kinase M2 (PKM2) has been shown to be among the crucial enzymes that regulate aerobic glycolysis in multiple tumour cells, its role in the treatment and prognosis of intrahepatic cholangiocarcinoma (ICC) remains unclear. This study primarily aimed to determine whether the expression status of PKM2 is potentially associated with the clinical outcomes of ICC. METHODS:PKM2 expression was evaluated in ICC cell lines and tissues via real-time quantitative reverse-transcription polymerase chain reaction, immunofluorescence assays, and Western blot, and its prognostic value was determined according to its impact on the overall survival of patients. RESULTS: We found that PKM2 is highly expressed in ICC, and this was correlated with patient survival. Moreover, we found that PKM2 knockdown could considerably inhibit ICC cell proliferation, invasion, and migration in vitro. CONCLUSIONS:PKM2 was overexpressed in ICC, and it may regulate proliferation, invasion, and migration and lead to poor prognosis. Thus, PKM2 might be a potential independent prognostic factor for ICC.
Authors: Jose J G Marin; Maria Reviejo; Meraris Soto; Elisa Lozano; Maitane Asensio; Sara Ortiz-Rivero; Carmen Berasain; Matias A Avila; Elisa Herraez Journal: Cancers (Basel) Date: 2021-12-21 Impact factor: 6.639
Authors: Marta Mascaraque-Checa; María Gallego-Rentero; Jimena Nicolás-Morala; Mikel Portillo-Esnaola; José M Cuezva; Salvador González; Yolanda Gilaberte; Ángeles Juarranz Journal: Mol Metab Date: 2022-04-09 Impact factor: 8.568